Table 1.
Serogroup 19/total (%) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Year | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 |
Total IPD isolates from children <5 yrs (all serotypes) | 245a | 141 | 71 | 81 | 99a,b | 73 | 95 | 73 | 66 | 60 | 80b | 58 | 63 |
Total serogroup 19 | 41a (17) | 33 (23) | 21 (30) | 35 (43) | 60a,b (61) | 42 (58) | 40 (42) | 40 (55) | 22 (33) | 13 (22) | 23a,b (29) | 19 (33) | 10 (16) |
Serotype 19F | 32c (13) | 19 (14) | 8 (11) | 4 (5) | 43,4 (4) | 5 (6) | 1 (1) | 3 (4) | 2 (3) | — | 74 (9) | 10 (17) | 6 (10) |
Serotype 19A | 93 (4) | 14 (10) | 13 (18) | 31 (38) | 56c (57) | 37 (51) | 39 (41) | 37 (55) | 20 (30) | 13 (22) | 16d (20) | 9 (16) | 4 (6) |
Vaccine Failuree - Serotype 19F | — | N/A | N/A | N/A | 3 (3) | 3 (4) | 1 (1) | — | 2 (3) | — | 3f,g (4) | 7 (12) | 4 (6) |
Vaccine Failuree - Serotype 19A | — | N/A | N/A | N/A | — | — | — | — | — | 5 (8) | 9g,i (11) | 6 (10) | 4 (6) |
Notes:
aIncrease in number and proportion of serogroup 19 between 2004 and 2008; p = 0.0001.
bDecrease in number and proportion of serogroup 19 between 2008 and 2014: p < 0.01.
cShift of predominant serotype from 19F to 19A after the introduction of PCV-7: p = 0.0001.
dIncrease in number and proportion of serotype 19F after introduction of PCV-13 p < 0.01.
eVaccine failure defined as IPD in children who had received the recommended 3 doses of PCV-7 and/or PCV-13.
fTwo vaccine failures were in children with co-morbidities associated with increased risk of IPD.
gOne vaccine failure case was reported in a child with co-morbidities associated with an increased risk of IPD.
hTwo serotype 19F vaccine failure cases where fully vaccinated with PCV-7, one case was fully vaccinated with PCV-13.
iAll 9 cases of 19A vaccine failure where fully vaccinated with PCV-13.